trending Market Intelligence /marketintelligence/en/news-insights/trending/1aFmhUIGNUZkNI5FA26e8A2 content esgSubNav
In This List

Alimera Sciences names CEO, CFO under succession plan

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Alimera Sciences names CEO, CFO under succession plan

Alimera Sciences Inc. promoted Richard Eiswirth Jr., who is also a president of the company, from CFO to CEO and named him to the board.

The executive change was made following the approval of a succession plan by Alimera's board that is intended to be effective Jan. 2.

Under the succession plan, C. Daniel Myers, co-founder of the company, retired as CEO and became a consultant to Alimera and nonexecutive board chairman.

Moreover, J. Philip Jones, the company's former vice president of finance, was appointed as CFO.

Philip Ashman, who was previously Alimera's senior vice president managing director Europe, was named as COO and senior vice president commercial operations Europe.

Alpharetta, Ga.-based Alimera Sciences is a pharmaceutical company, which engages in the research, development and commercialization of prescription ophthalmic, or eye-related, pharmaceuticals.